Cleared Traditional

REVISIED LABELING FOR ADX BENZODIAZEPINES (K880014) - FDA 510(k) Clearance

Class II Toxicology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K880014 · Abbott Laboratories · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1988
Decision
38d
Days
Class 2
Risk

K880014 is an FDA 510(k) clearance for the REVISIED LABELING FOR ADX BENZODIAZEPINES. Classified as Enzyme Immunoassay, Benzodiazepine (product code JXM), Class II - Special Controls.

Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on February 11, 1988 after a review of 38 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3170 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Abbott Laboratories devices

Submission Details

510(k) Number K880014 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 04, 1988
Decision Date February 11, 1988
Days to Decision 38 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
49d faster than avg
Panel avg: 87d · This submission: 38d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JXM Enzyme Immunoassay, Benzodiazepine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3170
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - JXM Enzyme Immunoassay, Benzodiazepine

All 51
Devices cleared under the same product code (JXM) and FDA review panel - the closest regulatory comparables to K880014.
DOUBLE ANTIBODY SERUM BENZODIAZEPINES
K890001 · Diagnostic Products Corp. · Jan 1989
TDX BENZODIAZEPINES SERUM
K883730 · Abbott Laboratories · Nov 1988
DOUBLE ANTIBODY BENZODIAZPINES #KBZD1, KBZD5
K883459 · Diagnostic Products Corp. · Sep 1988
REVISED LABELING FOR SYVA BENZODIAZEPINE ASSAYS
K874376 · Syva Co. · Nov 1987
REVISED LABELING FOR TDX BENZODIAZEPINES
K874489 · Abbott Laboratories · Nov 1987
REVISED LABELING FOR BENZODIAZEPINE TEST KIT
K874265 · Roche Diagnostic Systems, Inc. · Nov 1987